NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple Myeloma
ChIP-seq / ATAC-seq (genome binding and open chromatin) · human · 46 samples
- What it is
- ChIP-seq / ATAC-seq (genome binding and open chromatin)Where proteins bind the genome, or which regions are open and active.
- Organism
- Homo sapiens (human)
- Topic
- Multiple myelomaThis series is part of our curated briefing on it.
- Samples
- 46 samples: 20 conditions, mostly in duplicateGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- NSD2 Degradation Remediates the Oncogenic Cistrome in t(4;14) Multiple MyelomaBlood · 2026
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE328217_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: Look for peak files (.bed, .narrowPeak) and signal tracks (.bigWig) among the supplementary files; the raw reads are on ENA.
Also filed as BioProject PRJNA1454367 and SRA study SRP692363. Searching any of these in the dataset finder brings you back here.
Supports a between-group comparison across 40 samples.
How we read this: 20 replicated groups read from 46 sample titles; they account for 40 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9675118 KMS11_DMSO_Dup1_Day10 KMS11_DMSO_Dup1_Day
- GSM9675119 KMS11_DMSO_Dup1_Day4 KMS11_DMSO_Dup1_Day
- GSM9675120 KMS11_DMSO_Dup2_Day10 KMS11_DMSO_Dup2_Day
- GSM9675121 KMS11_DMSO_Dup2_Day4 KMS11_DMSO_Dup2_Day
- GSM9675122 KMS11_Dup1_Day0
- GSM9675123 KMS11_Dup2_Day0
- GSM9675124 KMS11_NSD2LDD_Dup1_Day10 KMS11_NSD2LDD_Dup1_Day
- GSM9675125 KMS11_NSD2LDD_Dup1_Day4 KMS11_NSD2LDD_Dup1_Day
- GSM9675126 KMS11_NSD2LDD_Dup2_Day10 KMS11_NSD2LDD_Dup2_Day
- GSM9675127 KMS11_NSD2LDD_Dup2_Day4 KMS11_NSD2LDD_Dup2_Day
- GSM9675128 KMS11_TKO_Dup1_Day0
- GSM9675129 KMS11_TKO_Dup2_Day0
- GSM9675130 KMS34_DMSO_Dup1_Day10 KMS34_DMSO_Dup1_Day
- GSM9675131 KMS34_DMSO_Dup1_Day4 KMS34_DMSO_Dup1_Day
- GSM9675132 KMS34_DMSO_Dup2_Day10 KMS34_DMSO_Dup2_Day
- GSM9675133 KMS34_DMSO_Dup2_Day4 KMS34_DMSO_Dup2_Day
- GSM9675134 KMS34_Dup1_Day0
- GSM9675135 KMS34_Dup2_Day0
- GSM9675136 KMS34_NSD2LDD_Dup1_Day10 KMS34_NSD2LDD_Dup1_Day
- GSM9675137 KMS34_NSD2LDD_Dup1_Day4 KMS34_NSD2LDD_Dup1_Day
- GSM9675138 KMS34_NSD2LDD_Dup2_Day10 KMS34_NSD2LDD_Dup2_Day
- GSM9675139 KMS34_NSD2LDD_Dup2_Day KMS34_NSD2LDD_Dup2_Day
- GSM9675140 KMS-11-100nM-Day14-Rep1 KMS-11-100nM-Day14
- GSM9675141 KMS-11-100nM-Day14-Rep2 KMS-11-100nM-Day14
- GSM9675142 KMS-11-100nM-Day7-Rep1 KMS-11-100nM-Day7
- GSM9675143 KMS-11-100nM-Day7-Rep2 KMS-11-100nM-Day7
- GSM9675144 KMS-11-1uM-Day14-Rep1 KMS-11-1uM-Day14
- GSM9675145 KMS-11-1uM-Day14-Rep2 KMS-11-1uM-Day14
- GSM9675146 KMS-11-1uM-Day7-Rep1 KMS-11-1uM-Day7
- GSM9675147 KMS-11-1uM-Day7-Rep2 KMS-11-1uM-Day7
- GSM9675148 KMS-11-DMSO-Day14-Rep1 KMS-11-DMSO-Day14
- GSM9675149 KMS-11-DMSO-Day14-Rep2 KMS-11-DMSO-Day14
- GSM9675150 KMS-11-DMSO-Day7-Rep1 KMS-11-DMSO-Day7
- GSM9675151 KMS-11-DMSO-Day7-Rep2 KMS-11-DMSO-Day7
- GSM9675152 KMS-34-100nM-Day14-Rep1 KMS-34-100nM-Day14
- GSM9675153 KMS-34-100nM-Day14-Rep2 KMS-34-100nM-Day14
- GSM9675154 KMS-34-100nM-Day7-Rep1 KMS-34-100nM-Day7
- GSM9675155 KMS-34-100nM-Day7-Rep2 KMS-34-100nM-Day7
- GSM9675156 KMS-34-1uM-Day14-Rep1 KMS-34-1uM-Day14
- GSM9675157 KMS-34-1uM-Day14-Rep2 KMS-34-1uM-Day14
+ 6 more — browse all 46 samples with per-sample file links →
- GSE155631 Oncogenic mechanisms of DIS3 mutations in Multiple Myeloma 62 samples same disease briefing · shares oncogenic, multiple, myeloma
- GSE161195 Single cell RNA-seq of relapsed and refractory multiple myeloma patients defines new resistance pathways and targeted treatments 213 samples same disease briefing · shares multiple, myeloma
- GSE167969 ATAC-seq and RNA-Seq of Multiple Myeloma 46 samples same disease briefing · shares multiple, myeloma
- GSE148715 “Direct to Drug” screening as a precision medicine tool in multiple myeloma 38 samples same disease briefing · shares multiple, myeloma
- GSE167968 RNA-seq of Multiple Myeloma 33 samples same disease briefing · shares multiple, myeloma
- GSE179453 Expression data from control-knockdown (CTR-KD) and MAST4-KD human multiple myeloma (MM) cell lines 6 samples same disease briefing · shares multiple, myeloma
- GSE167042 Splicing modulation increases BCL2 dependence and sensitizes Multiple Myeloma cells to Venetoclax 4 samples same disease briefing · shares multiple, myeloma
- GSE178442 Genome-wide maps of transcription in DEAF1 overexpression(OE) and wildtype(WT) cells in Multiple Myeloma 4 samples same disease briefing · shares multiple, myeloma
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.